Navigation Links
Global Intraocular Lenses Industry
Date:7/29/2013

est of Europe Historic Review for Intraocular

Lenses by Product Segment - Standard Intraocular Lenses and

Premium Intraocular Lenses Markets Independently Analyzed

with Annual Sales Figures in US$ Million for Years 2005

through 2009 (includes corresponding Graph/Chart) III-83

 

Table 67: Rest of Europe 14-Year Perspective for

Intraocular Lenses by Product Segment - Percentage Breakdown

of Dollar Sales for Standard Intraocular Lenses and Premium

Intraocular Lenses Markets for Years 2005, 2012 & 2018

(includes corresponding Graph/Chart) III-84

 

5. ASIA-PACIFIC III-85

A.Market Analysis III-85

Current and Future Analysis III-85

An Overview of the Asia-Pacific Cataract Market III-85

Lethargic Adoption Typifies Premium IOLs Market in Asia-

Pacific III-85

Demand in Asia-Pacific Basks around High-Growth Indian and

Chinese Markets III-86

B.Market Analytics III-86

Table 68: Asia-Pacific Recent Past, Current & Future

Analysis for Intraocular Lenses by Geographic Region -

China, India and Rest of Asia-Pacific Markets Independently

Analyzed with Annual Sales Figures in US$ Million for Years

2010 through 2018 (includes corresponding Graph/Chart) III-86

 

Table 69: Asia-Pacific Recent Past, Current & Future

Analysis for Intraocular Lenses by Product Segment -

Standard Intraocular Lenses and Premium Intraocular Lenses

Markets Independently Analyzed with Annual Sales Figures in

US$ Million for Years 2010 through 2018 (includes

corresponding Graph/Chart) III-87

 

Table 70: Asia-Pacific Historic Review for Intraocular

Lenses by Geographic Region - China, India'/>"/>

SOURCE Reportlinker
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27

Related medicine technology :

1. Global Breast Pumps Industry
2. Global Calcium Carbonate Industry
3. China Heart Valve Market and Heart Lung Machine Industry Global Analysis in New Research Reports
4. The Global Proteomics Market to Grow At A CAGR Of 14.43 Percent over the Period 2012-2016
5. Global Vascular Stents Market 2012-2016 Report with Abbott Laboratories, Medtronic Inc. and Boston Scientific Corp. Dominating
6. The Global Market for Intravascular Ultrasound Tools and Ancillary Equipment
7. Peripheral Neuropathy (Sensory Neuropathy) Global Clinical Trials Review, H1, 2013
8. Computational Biology Market - Global Industry Analysis, Size, Share, Growth, Trend
9. Water Treatment Industry Reports: Equipment Research for US & Global Wastewater Treatment Markets
10. Global Herbal Supplements and Remedies Industry
11. Pain Management Devices Market (Electrical Stimulators, Radiofrequency Ablation, Analgesic Pumps, Neurostimulation Devices) Is Expected to Reach USD 5.0 Billion Globally in 2018: Transparency Market Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -   The issue: ... tests confirmed it contains two undeclared amphetamine-like drug substances ... distributor, Empire Health Distribution of Terrebonne, Quebec ... across Canada .  Jetfuel Superburn is ... and increased energy. What consumers should ...
(Date:12/24/2014)... N.Y. , Dec. 24, 2014 Kinex ... dosed with KX2-361 at Roswell Park Cancer Institute. ... small molecule drug that has shown potent inhibitory activity ... including those that are resistant to Temozolomide (T98G), the ... glioma. In a well-established brain tumor mouse model, KX2-361 ...
(Date:12/24/2014)... and FARMINGTON, Conn. , Dec. ... MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific ... significant unmet medical need and commercial potential, today ... placement of 2,050,000 shares of its common stock ... of its common stock.  Funds under the management ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 2Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4
... and Pipeline Analysis, 4th Edition Now Available... -- DALLAS, September 28, 2010 ... ... --> ... = ,; var first_result; // Results are keyed by longUrl, so we need to grab the first ...
... SCOLR Pharma, Inc. (NYSE AMEX: DDD ... as the Chairman of its Board of Directors.  Johnson ... the Board.   Johnson previously served as ... Under Johnson,s leadership, Matrixx successfully developed and launched the ...
Cached Medicine Technology:Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 2Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 3Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 4Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 5Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 6Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 7Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 8Emerging Cancer Vaccines Market: Forecasts, Developments and Pipeline Analysis, 4th Edition Now Available at ReportsandReports 9SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 2SCOLR Pharma, Inc. Names Carl Johnson as Chairman; Former Chairman Michael Taglich Remains as Director 3
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
(Date:12/25/2014)... BambooFlooringChina.com sells many bamboo products and the business ... company announces big discounts on its bamboo mats ... BambooFlooringChina.com is the world’s leader in bamboo flooring. According ... Jan. 20, 2015. , The bamboo mats are made ... thread. All the bamboo strips for the mats are ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional ... all of the models at LunaDress.co.uk come with big discounts, up ... wedding veil can turn out to be a most exciting memory ... can always bring surprise to a wedding. On the updated fashion ... choose veils for a big day . , Going out with ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... tries its best to translate the experience of dress ... introduced its new collection of 2015 prom dresses, and ... prom outfits are guaranteed to contain the perfect designs ... designed for 2015. Anyone who wants to buy ... before Jan. 26, 2015, the deadline of the promotion. ...
Breaking Medicine News(10 mins):Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2Health News:Various Styles of Bamboo Mats in Many Colors from BambooFlooringChina.com 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Angelweddingdress 2015 Prom Dresses Online Now 2
... Dynavax Technologies,Corporation (Nasdaq: DVAX ) announced today ... present an overview of the,company at two investor conferences ... will present at the CIBC World Markets 18th Annual,Healthcare ... ET (5:35,a.m. PT). In addition, Ostrach will present at ...
... Inc. today,announced the initiation of a phase 1 ... treatment of hypertension. AR9281 is a "first-in-class,",orally-active inhibitor ... the treatment of hypertension. The trial will enroll ... the safety, tolerability,pharmacokinetics and pharmacodynamics for single ascending ...
... Nov. 1 Amira Pharmaceuticals, Inc. announced,completion of ... Amira,s,internally discovered oral drug candidate for the treatment ... also announced the start,of a Phase 1 trial ... targets the,same inflammatory response. AM103 and AM803 ...
... NAPLES, Fla., Nov. 1 MediaBrains Inc., a ... http://www.agingcare.com . The,website will focus on the needs ... for connecting caregivers with expert information,resources, products and ... Month. The caregiver market represents one of ...
... 1, Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) the,global ... Q3 2007 Financial Highlights - Product sales up 41% ... $608.7 million; - Net cash provided by operating activities ... growth now expected to be at least 30% (Q2 guidance: ...
... - An Innovative Approach to Preventing Kidney Damage during ... ... Systems Inc. (Amex: PLC ), a,company focused on innovative cardiac ... RenalGuard,System(TM) during Renal Week, the American Society of Nephrology,s 40th,Annual Meeting ...
Cached Medicine News:Health News:Dynavax to Present at CIBC World Markets and Acumen BioFin Rodman and Renshaw Healthcare Conferences 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 2Health News:Arete Therapeutics Initiates Phase 1 Clinical Trial For AR9281 as a First-in-Class Antihypertensive Agent 3Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 2Health News:Amira Pharmaceuticals Announces Favorable Phase 1 Clinical Trial Results for Lead Product Candidate AM103 and Initiates Clinical Studies for the 2nd Entry Molecule for the Treatment of Respiratory and Cardiovascular Disease 3Health News:Agingcare.com Launches to Meet Information and Networking Demands for Booming 34 Million Caregiver Market 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 2Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 3Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 4Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 5Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 6Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 7Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 8Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 9Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 10Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 11Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 12Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 13Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 14Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 15Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 16Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 17Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 18Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 19Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 20Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 21Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 22Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 23Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 24Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 25Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 26Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 27Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 28Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 29Health News:Further Upgrade to 2007 Financial Guidance Based on Strong Revenue Growth; VYVANSE Demand on Track 30
Both versions of the UltraSling II provide immobilization for rotator cuff repairs, capusular shifts, Bankhart repairs, glenohumeral dislocations/subluxation and soft tissue repairs/strains....
Unique V-lock strapping system prevents roll and shifting to provide secure shoulder immobilization...
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... Effective spinal bracing is a critical component ... surgical stabilization. The Aspen® Lumbosacral Bracing System™ ... provide a high degree of immobilization, unparalled ... patients . . . even if they ...
Medicine Products: